0.5 mg epinephrine

Phase 2

ARS Pharmaceuticals, Inc. (SPRY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Urticaria Chronic

View Full Landscape

Drug Information

Target Indication

Urticaria Chronic

Clinical Trial

NCT06927999

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Neffy

Emergency treatment of allergic reactions, including anaphylaxis.

View on EMA

EMA8/22/2024

Eurneffy

Eurneffy is indicated in the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens as well as idiopathic or exercise induced anaphylaxis. Treatment is indicated for adults and children aged 4 years and over with a body weight of 15 kg or more.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SPRY

ARS Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

ARS-1Phase 2

Asthma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts